H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...

HC Wainwright reissued their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) in a research report sent ...

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

HC Wainwright reiterated their neutral rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research report sent to ...

Looking at options history for Cleanspark CLSK we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

On Tuesday, H.C. Wainwright reaffirmed a positive outlook on OKYO Pharma Ltd. (NASDAQ: OKYO), maintaining a Buy rating and a $7.00 price target. Currently trading at $1.10, with a market ...

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...